CareCloud (CareCloud) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is CareCloud Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of CareCloud is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of CareCloud's Risk Assessment

For the Health Information Services subindustry, CareCloud's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CareCloud's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, CareCloud's Risk Assessment distribution charts can be found below:

* The bar in red indicates where CareCloud's Risk Assessment falls into.

CareCloud (NAS:CCLD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

CareCloud Risk Assessment Related Terms

Thank you for viewing the detailed overview of CareCloud's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

CareCloud (CareCloud) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » CareCloud Inc (NAS:CCLD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

CCLDP.PFD:USA MTB0:Germany MTB:Germany

Address

7 Clyde Road, Somerset, NJ, USA, 08873

Website

https://www.carecloud.com

CareCloud Inc is a healthcare information technology company. It provides a full suite of proprietary cloud-based solutions and related business services. Its Software-as-a-Service platforms include practice management (PM), electronic health record (EHR), business intelligence, telehealth, patient experience management (PXM) solutions, and robotic processing automation (RPA) bots, along with complementary software tools and business services such as revenue cycle management (RCM), premiere healthcare consulting and implementation services, and on-demand workforce staffing capabilities for high-performance medical groups and health systems nationwide. The operating segments of the group are Healthcare IT, which is the key revenue generating segment, and Practice Management.

Executives

Mahmud Ul Haq	director, 10 percent owner, officer: Chief Executive Officer	7 CLYDE ROAD, SOMERSET NJ 08873
Lawrence Steven Sharnak	director	7393, ORANGEWOOD LANE, BOCA RATON FL 33433
Anne Busquet	director	390 PARK AVE 4TH FLR, NEW YORK NY 10022
A Hadi Chaudhry	officer: President	7 CLYDE ROAD, SOMERSET NJ 08873
Nathalie Grey Garcia	officer: General Counsel & Secretary	7 CLYDE ROAD, SOMERSET NJ 08873
Lawrence J. Steenvoorden	officer: Chief Financial Officer	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Stephen Andrew Snyder	director, officer: President	7 CLYDE ROAD, SOMERSET NJ 08873
Bill Korn	officer: Chief Financial Officer	61 DARREN DRIVE, BASKING RIDGE NJ 07920
John N Daly	director	390 STANWICH ROAD, GREENWICH CT 06830
Kimberly J Grant	officer: General Counsel & Secretary	7 CLYDE ROAD, SOMERSET NJ 08873
Cameron Munter	director	295 WEST ORANGE GROVE AVE, SIERRA MADRE CA 91024
Shruti H Patel	officer: Interim Corporate Secretary	7 CLYDE ROAD, SOMERSET NJ 08873
Amritpal K. Deol	officer: See Remarks	7 CLYDE ROAD, SOMERSET NJ 08873
Norman Roth	officer: See Remarks	7 CLYDE ROAD, SOMERSET NJ 08873
Brendan Patrick Harney	officer: See Remarks	7 CLYDE ROAD, SOMERSET NJ 08873